Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDATOR: Mammostrat Validation in Neoadjuvant Breast Cancer
NCT02067416Phase 2Withdrawn
- Start
- Jul 2012
- Primary completion
- Jun 2014
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms). Primary endpoint: Mammostrat score clinical response rates to chemotherapy at 2 years. Planned start Jul 2012; status: withdrawn.
Beyond the preview
Go deeper on NCT02067416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067416.